In the current market session, TTM Technologies Inc. TTMI stock price is at $37.00, after a 0.24% decrease. However, over the past month, the company's stock increased by 23.79%, and in the past year, by 91.19%.

Investors with a lot of money to spend have taken a bullish stance on Netflix NFLX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Investors with a lot of money to spend have taken a bullish stance on Micron Technology MU. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Digital Turbine reports stronger-than-expected Q4 earnings and revenue, with EPS of $0.10 and revenue of $119.15 million. The stock surged over 50% as investors reacted positively to improved margins, 66% EBITDA growth and fiscal 2026 revenue guidance.

"The panic of '22 showed that much like in TradFi, liquidity and solvency are intimately bound up with each other," said Cycles' Ethan Buckman.

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Tuesday. The Dow traded down 0.70% to 42,217.89 while the NASDAQ fell 0.87% to 19,530.08. The S&P 500 also fell, dropping, 0.79% to 5,985.31. Energy shares jumped by 1.4% on Tuesday.

Lenacapavir could cost just $25 to produce annually but may be priced at $25,000. Gilead's global licensing excludes nations with a third of new HIV cases. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.

Redwire stock are down nearly 19% after announcing a $260 million public offering of common shares, raising dilution concerns. The proceeds will be used to fund growth, repurchase preferred stock, and repay debt from a past acquisition.

Regencell shares are up more than 59,000% in 2025. Regencell does not generate any revenue or has received regulatory approval for its products. Live on Wednesday June 18: 3 Summer "Power Patterns" Are About to Trigger ( One With 90% Win Rate ) . See Them Here. Regencell Bioscience Holdings ...